Germany's strategic innovation unit and business incubator, Evonik Creavis, has opened a new satellite innovation facility in Cambridge, in the US state of Massachusetts.

The facility, named Satellite Innovation, includes both labs and offices. Initially, Satellite Innovation will focus on research and development (R&D) activities for healthcare innovations such as nucleic acid-based medicines.

The new facility will also accelerate Evonik’s venture capital activities in the life sciences sector in the region. The investments will be focused on drug delivery technologies, cell culture, tissue engineering, and medical implants.

Anil Saxena, head of the facility said, “With our new Innovation Satellite in Cambridge, we are extending an invitation for collaboration to the brilliant minds across this dynamic region.”

Ralph Marquardt, chief innovation officer of Evonik said, "Addressing the global challenges of our time requires the worldwide collaboration of competent partners, and we are looking forward to jointly developing innovative solutions. We are strengthening regional R&D in North America and Asia to benefit from innovative ideas outside of Europe and be closer to our customers in those regions,"

Creavis’ Cambridge Innovation Satellite adds to Evonik’s ongoing R&D expansion in the US. In March 2023, the company broke ground on a new $220m lipid innovation centre in Lafayette, Indiana. Furthermore, in September 2022, it opened a new innovation hub in Allentown, Pennsylvania.

Headquartered in the German city of Essen, Evonik Industries AG has production plants in over 27 countries with around 33,000 employees globally.

"Evonik Creavis opens new satellite innovation facility in Cambridge, Massachusetts" was originally created and published by Investment Monitor, a GlobalData owned brand.

 

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.